Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).

Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS

Clinical therapeutics27 Oct 2017Cited by 18 (Europe PMC)

PMID29110972DOI10.1016/j.clinthera.2017.10.002PepBankPUB-29110972

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In insulin-treated T2DM patients, added dulaglutide improved IW-SP scores more than placebo, with a difference of +6.06.
In plain wordsIn people with diabetes receiving glargine, added dulaglutide improved weight self-perception more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight self-perception score
Study
n: not reported in source
Comparator
Placebo added to glargine
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Studied dose
1.5 mg weekly · 28 weeksAs given in this study (human).
Measurements
IW-SP transformed total score, LS mean difference
6.06 transformed score
dulaglutide/glargine versus placebo/glargine, 28 weeks
Source sentences
Summary
At 28 weeks, improvements observed in the transformed total scores on the IW-SP and DHP-18 Disinhibited Eating domain were significantly greater with dulaglutide/glargine compared with placebo/glargine (least squares mean differences, +6.06 [P = 0.019] and -4.50 [P = 0.017], respectively).
Report a problemFND-2911097201
02HumanRandomized controlled trialEfficacy outcome
In insulin-treated T2DM patients, added dulaglutide improved disinhibited eating scores more than placebo, with a difference of -4.50.
In plain wordsIn people with diabetes receiving glargine, added dulaglutide improved disinhibited eating scores more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDisinhibited eating score
Study
n: not reported in source
Comparator
Placebo added to glargine
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Studied dose
1.5 mg weekly · 28 weeksAs given in this study (human).
Measurements
DHP-18 Disinhibited Eating score, LS mean difference
−4.5 transformed score
dulaglutide/glargine versus placebo/glargine, 28 weeks
Source sentences
Summary
At 28 weeks, improvements observed in the transformed total scores on the IW-SP and DHP-18 Disinhibited Eating domain were significantly greater with dulaglutide/glargine compared with placebo/glargine (least squares mean differences, +6.06 [P = 0.019] and -4.50 [P = 0.017], respectively).
Report a problemFND-2911097202
03HumanRandomized controlled trialEfficacy outcome
In insulin-treated T2DM patients, EQ-5D-5L scores did not differ significantly between added dulaglutide and placebo.
In plain wordsIn people with diabetes receiving glargine, overall health scores did not differ significantly with added dulaglutide versus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeEQ-5D-5L quality of life
Study
n: not reported in source
Comparator
Placebo added to glargine
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Studied dose
1.5 mg weekly · 28 weeksAs given in this study (human).
Source sentences
Summary
There were no significant overall between-treatment differences in quality of life as measured by the EQ-5D-5L or the Barriers to Activities and Psychological Distress domains of the DHP-18.
Report a problemFND-2911097203
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated T2DM patients, barriers-to-activities scores did not differ significantly between added dulaglutide and placebo.
In plain wordsIn people with diabetes receiving glargine, activity-barrier scores did not differ significantly with added dulaglutide versus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBarriers to activities
Study
n: not reported in source
Comparator
Placebo added to glargine
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Studied dose
1.5 mg weekly · 28 weeksAs given in this study (human).
Source sentences
Summary
There were no significant overall between-treatment differences in quality of life as measured by the EQ-5D-5L or the Barriers to Activities and Psychological Distress domains of the DHP-18.
Report a problemFND-2911097204
05HumanRandomized controlled trialEfficacy outcome
In insulin-treated T2DM patients, psychological-distress scores did not differ significantly between added dulaglutide and placebo.
In plain wordsIn people with diabetes receiving glargine, distress scores did not differ significantly with added dulaglutide versus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePsychological distress
Study
n: not reported in source
Comparator
Placebo added to glargine
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Studied dose
1.5 mg weekly · 28 weeksAs given in this study (human).
Source sentences
Summary
There were no significant overall between-treatment differences in quality of life as measured by the EQ-5D-5L or the Barriers to Activities and Psychological Distress domains of the DHP-18.
Report a problemFND-2911097205

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In T2DM patients, 95% rated the dulaglutide Single-Use Pen easy or very easy to use at 28 weeks.
In plain wordsIn people with diabetes, 95% rated the dulaglutide pen easy or very easy to use.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePen ease of use
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Measurements
Rated easy or very easy to use
95%
dulaglutide Single-Use Pen, 28 weeks
Source sentences
Summary
Of all patients, 95% reported that overall, the dulaglutide SUP was "easy" or "very easy" to use at 28 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2911097206
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In T2DM patients, most liked dulaglutide pen features, with needle-related features receiving the highest ratings.
In plain wordsMost people with diabetes liked the dulaglutide pen features, especially those related to the needle.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePen feature preferences
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Source sentences
Summary
Device-features scores showed that most patients liked the dulaglutide SUP features, with the 3 highest-rated items relating specifically to features of the needle (not having to touch the needle, not having to attach the needle, and automatic insertion).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2911097207
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In T2DM patients, approximately 90% agreed or strongly agreed that they were satisfied with the dulaglutide pen injection experience.
In plain wordsApproximately 90% of people with diabetes reported satisfaction with the dulaglutide pen injection experience.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePen injection satisfaction
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Quality of life · Whole body
Measurements
Satisfied with injection experience
≈ 90%
dulaglutide single-use pen, week 28
Source sentences
Summary
The majority of patients (~90%) "agreed" or "strongly agreed" that they were satisfied with the overall dulaglutide SUP injection experience at 28 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2911097208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02152371

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Eli Lilly and Companyn = 300May 2014 to Oct 2015

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.